Janus Henderson Group
PTCT icon

Janus Henderson Group’s PTC Therapeutics PTCT Stock Holding History

Janus Henderson Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$490M Buy
7,193,433
+2,342,101
+48% +$166M 0.23% 103
2025
Q4 		$369M Buy
4,851,332
+1,077,776
+29% +$78.3M 0.17% 132
2025
Q3 		$232M Buy
3,773,556
+598,541
+19% +$31.2M 0.11% 169
2025
Q2 		$155M Buy
3,175,015
+258,286
+9% +$12.3M 0.08% 210
2025
Q1 		$158M Buy
2,916,729
+590,814
+25% +$29.5M 0.09% 205
2024
Q4 		$105M Buy
2,325,915
+455,698
+24% +$19.5M 0.05% 272
2024
Q3 		$69.4M Sell
1,870,217
-1,111,342
-37% -$37.2M 0.04% 324
2024
Q2 		$91.1M Sell
2,981,559
-688,257
-19% -$22.3M 0.05% 281
2024
Q1 		$107M Buy
3,669,816
+1,057,223
+40% +$29.6M 0.06% 255
2023
Q4 		$72M Sell
2,612,593
-459,727
-15% -$10.5M 0.04% 306
2023
Q3 		$68.8M Sell
3,072,320
-524,430
-15% -$19.5M 0.05% 298
2023
Q2 		$146M Buy
3,596,750
+400,446
+13% +$19.6M 0.09% 204
2023
Q1 		$155M Buy
3,196,304
+1,169,162
+58% +$53.4M 0.1% 191
2022
Q4 		$77.4M Sell
2,027,142
-50,722
-2% -$2.11M 0.06% 290
2022
Q3 		$104M Sell
2,077,864
-57,812
-3% -$2.83M 0.08% 231
2022
Q2 		$85.6M Sell
2,135,676
-546,298
-20% -$19.2M 0.06% 282
2022
Q1 		$100M Sell
2,681,974
-1,219,423
-31% -$47M 0.05% 319
2021
Q4 		$155M Buy
3,901,397
+326,210
+9% +$12.5M 0.06% 271
2021
Q3 		$133M Buy
3,575,187
+71,273
+2% +$2.93M 0.06% 302
2021
Q2 		$148M Buy
3,503,914
+434,774
+14% +$18.6M 0.06% 293
2021
Q1 		$145M Buy
3,069,140
+72,719
+2% +$4.32M 0.07% 285
2020
Q4 		$183M Buy
2,996,421
+977,858
+48% +$57.6M 0.09% 242
2020
Q3 		$94.4M Buy
2,018,563
+201,752
+11% +$9.93M 0.05% 345
2020
Q2 		$92.2M Buy
1,816,811
+47,054
+3% +$2.31M 0.05% 338
2020
Q1 		$78.9M Buy
1,769,757
+283,095
+19% +$14.3M 0.05% 335
2019
Q4 		$71.4M Buy
1,486,662
+133,357
+10% +$5.67M 0.04% 479
2019
Q3 		$45.8M Sell
1,353,305
-37,613
-3% -$1.64M 0.02% 601
2019
Q2 		$62.6M Sell
1,390,918
-27,561
-2% -$1.09M 0.03% 519
2019
Q1 		$53.4M Buy
+1,418,479
New +$47.6M 0.03% 559

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Janus Henderson Group's PTCT Position: Q1 2026 in Review

Janus Henderson Group increased its PTC Therapeutics (PTCT) stake by 48% in Q1 2026, buying an estimated $166M and bringing the position to 7,193,433 shares worth $490M. The position accounts for 0.23% of the portfolio, ranked #103.

Janus Henderson Group first reported a position in PTCT in Q1 2019 and has held it in 29 quarters since. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Janus Henderson Group held 7,193,433 shares of PTC Therapeutics worth $490M as of Q1 2026.
  • Janus Henderson Group bought 2,342,101 PTC Therapeutics shares in Q1 2026, an estimated $166M.
  • PTC Therapeutics made up 0.23% of Janus Henderson Group's portfolio in Q1 2026, its #103 holding.
  • Janus Henderson Group first reported a position in PTC Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.